Completed PHASE4 INTERVENTIONAL 2-arm NCT00654368

CAMEO: Canadian Methotrexate and Etanercept Outcome Study

Canadian Methotrexate and Etanercept Outcome Study: An Open Label Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in the Treatment of Rheumatoid Arthritis (CAMEO)

Sponsor: Amgen

Conditions Rheumatoid Arthritis

Interventions Etanercept Methotrexate

Updated 6 times since 2017 Last updated: Jul 14, 2014 Started: Jun 30, 2008 Primary completion: Dec 31, 2012 Completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00654368, this PHASE4 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Amgen, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bowmanville, Canada , Brampton, Canada , Burlington, Canada , Hamilton, Canada , Laval, Canada , London, Canada , Mississauga, Canada , Montreal, Canada , Newmarket, Canada , Ottawa, Canada and 13 more locations